---
title: "BUZZ-Astria rises on FDA's orphan drug tag for its genetic disorder treatment"
description: "Shares of drug developer Astria Therapeuticsrise about 3% to $11.45Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodemaAngiodema causes swelling of arms, face, "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/215642271.md"
published_at: "2024-09-30T15:43:01.000Z"
---

# BUZZ-Astria rises on FDA's orphan drug tag for its genetic disorder treatment

> Shares of drug developer Astria Therapeuticsrise about 3% to $11.45Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodemaAngiodema causes swelling of arms, face, legs and intestinal tractOrphan drug tag based on early-to-mid-stage trial, in which drug showed reduced monthly swelling attack rates by 90% to 96% when dosed once or twice over 6 monthsCo expects to get additional results from trial in Q4 and progress navenibart into late-stage trial initiating in Q1 2025Including session’s move, stock up ~47.3% YTD

Shares of drug developer Astria Therapeutics (ATXS.O) rise about 3% to $11.45

Co receives FDA orphan drug designation for navenibart for treatment of hereditary angiodema

Angiodema causes swelling of arms, face, legs and intestinal tract

Orphan drug tag based on early-to-mid-stage trial, in which drug showed reduced monthly swelling attack rates by 90% to 96% when dosed once or twice over 6 months

Co expects to get additional results from trial in Q4 and progress navenibart into late-stage trial initiating in Q1 2025

Including session’s move, stock up ~47.3% YTD

### Related Stocks

- [ATXS.US - Astria Therapeutics](https://longbridge.com/en/quote/ATXS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Egetis Therapeutics Submits Emcitate NDA to FDA and Expects Regulatory Decision in September 2026 | Egetis Therapeutics AB has completed its rolling U.S. New Drug Application (NDA) submission for Emcitate® (tiratricol) a | [Link](https://longbridge.com/en/news/274995320.md) |
| Astria Therapeutics to Be Acquired by BioCryst Pharmaceuticals | Astria Therapeutics is set to merge with BioCryst Pharmaceuticals, becoming a wholly owned subsidiary. A registration st | [Link](https://longbridge.com/en/news/270660274.md) |
| Astria Therapeutics Reports Q3 2025 Results and BioCryst Acquisition | Astria Therapeutics, Inc. (ATXS) reported its Q3 2025 results, announcing its acquisition by BioCryst Pharmaceuticals, e | [Link](https://longbridge.com/en/news/265639741.md) |
| Astria Therapeutics to Present Final ALPHA-STAR Trial Results for Navenibart in Hereditary Angioedema | Astria Therapeutics Inc. will present final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart for here | [Link](https://longbridge.com/en/news/263738231.md) |
| Astria Therapeutics Reports Positive Phase 1b/2 Trial Results for Navenibart in HAE Patients | Astria Therapeutics Inc. reported positive results from the ALPHA-STAR Phase 1b/2 trial of navenibart (STAR-0215) for he | [Link](https://longbridge.com/en/news/264660894.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
